weight loss drug

2025.08.01

19:45

Novo Nordisk and Eli Lilly rose in pre-market trading as the US may consider insurance coverage for weight loss drugs.

Novo Nordisk shares rose 1.9% in pre-market trading, while Eli Lilly and Company rose 1.5% following reports that the United States will consider insurance coverage for weight loss drugs.

19:45

Novo Nordisk (NVO.N) rose 1.9% in premarket trading, while Eli Lilly (LLY.N) rose 1.5% following reports that the United States will consider insurance coverage for weight loss drugs.

04:13

US stocks close: All three major stock indexes fall, while new stock Figma soars 250%

The three major US stock indices closed lower, with the Dow Jones Industrial Average down 0.74%, the Nasdaq down 0.03%, and the S&P 500 down 0.37%. Popular technology stocks saw mixed gains and losses, with Meta gaining over 11% and Microsoft rising nearly 4%, though its market capitalization fell below $40,000. Arm fell over 13%, Tesla fell over 3%, and Google and Broadcom fell over 2%. Semiconductor equipment and materials, and weight loss drug stocks saw the largest declines, with Novo Nordisk down nearly 6%, KLA-Tencor down nearly 5%, ASML down over 3%, and Eli Lilly and Pfizer down over 2%. Design software giant Figma saw its stock price surge 250% on its first day of trading.

2025.07.30

04:11

US stock market closes: All three major stock indexes fall, Novo Nordisk falls more than 20%

The three major US stock indices closed lower, with the Dow Jones Industrial Average down 0.46%, the Nasdaq down 0.38%, and the S&P 500 down 0.3%. Most popular technology stocks fell, with Meta dropping over 2%, Intel, Apple, and Tesla down over 1%, and AMD up over 2%. Weight loss drug and integrated logistics sectors plummeted, with Novo Nordisk down over 21%, UPS down over 10%, Eli Lilly down over 5%, and FedEx down over 3%. The oil and gas sector strengthened, with ExxonMobil, Shell, and Imperial Oil rising over 1%.

2025.07.29

20:55

Novo Nordisk (NVO.N) Chief Financial Officer: Our latest market research still shows that 1 million U.S. patients are taking combination weight loss drugs.

19:51

Copenhagen's OMXC 20 index fell 13% after diet drug maker Novo Nordisk cut its 2025 guidance.

19:29

Weight loss drug maker Novo Nordisk (NVO.N) saw its pre-market losses extend to 15%. The company now expects sales growth of 8%-14% in 2025, lower than its previous forecast of 13%-21%.

19:10

Novo Nordisk (NVO.N): The downward revision of its fiscal year sales forecast is related to declining sales of its weight loss drug Wegovy in the United States.

2025.07.22

10:07

The A-share weight loss drug sector rose in the short term, with Livzon Group hitting the daily limit, Kangyuan Pharmaceutical rising more than 7%, Aimei and Borri Pharmaceutical rising more than 6%, and Hanyu Pharmaceutical and Sichuan Shuangma following suit. On the news front, the World Health Organization said that new guidelines for the treatment of adult obesity based on GLP-1 therapy are scheduled to be officially released in September.

10:03

World Health Organization: New guidelines for the treatment of adult obesity based on GLP-1 therapy are planned to be officially released in September

Reporters learned that the World Health Organization (WHO) is developing new guidelines for the treatment of adult obesity based on GLP-1 therapy, which is scheduled to be officially released in September 2025. The guidelines are developed by an independent Guideline Development Group (GDG), whose members include experts in the field of obesity, epidemiologists, clinical management experts, pharmacologists, health economists, public health program experts and policy makers to ensure that the guidelines meet the strict standards of the World Health Organization. It is reported that the purpose of the guidelines is to clarify the clinical indications, applications and planning considerations of GLP 1 RAs. The guidelines are expected to be the first time that the World Health Organization has officially recommended the use of weight loss drugs to treat adult obesity. The move marks a major policy shift for the global health agency in addressing the growing obesity crisis.

2025.07.09

10:21

Concepts such as CRO, weight loss drugs, and innovative drugs continued to recover, with Purui rising more than 14%, Jiuzhitang hitting the daily limit, and Celecoxib rising more than 8%. Stocks such as Shanghai YiZhong, Yinosi, and Aosaikang followed suit.

2025.07.08

21:15

Novo Nordisk (NVO.N): New doses of its weight loss drug Wegovy have been submitted to the European Medicines Agency for approval. One-third of trial participants achieved a weight loss of 25% or more.

2025.07.07

15:01

A-share closing review: Shanghai Composite Index fluctuated slightly higher, power and power grid equipment sectors collectively rose sharply

The three major A-share indices rose and fell today. As of the close, the Shanghai Composite Index rose 0.02%, the Shenzhen Component Index fell 0.7%, the ChiNext Index fell 1.21%, and the Beijing Stock Exchange 50 Index fell 0.93%. The total market turnover was 1.227 trillion yuan, a decrease of 227.4 billion yuan from the previous day. More than 3,200 stocks rose in the entire market. In terms of sector themes, the CSSC, power, power grid equipment, cross-border payment, real estate, diversified finance, and football sectors led the gains; weight loss drugs, CPO, AI PC, and 6G concept stocks led the declines. On the market, the power and power grid equipment sectors collectively rose sharply, and more than 10 stocks such as Xinling Electric, Great Wall Electric, and Shaoneng Co., Ltd. hit the daily limit. The cross-border payment sector performed actively, and stocks such as Beijing North, Qingdao King King, and Xinyada hit the daily limit. The real estate sector maintained its gains, and stocks such as Chongqing Development, Nanshan Holdings, and Shahe Co., Ltd. closed the board. Football concept stocks rose, and Gongchuang Lawn and Shuangxiang Co., Ltd. both hit the daily limit. Innovative drug concept stocks rose and then fell. Sinovac Biotech fell 17% during the day. Nanjing Xinbai, Rejing Biotech and Yipinhong were the biggest losers. Most CPO concept stocks adjusted, with Dongshan Precision, Shengyi Electronics and Zhaolong Interconnect leading the decline. The memory chip sector performed poorly. Chengbang shares hit the limit down in the late trading. Infront Micro, Haoshanghao and Dawei shares followed suit.

11:30

A-share midday review: ChiNext Index fell 1.25% in half a day, while power and cross-border payment sectors strengthened against the market trend

The three major A-share indices fell collectively in the morning trading. As of noon, the Shanghai Composite Index fell 0.21%, the Shenzhen Component Index fell 0.7%, the ChiNext Index fell 1.25%, and the Beijing Stock Exchange 50 Index fell 0.96%. The market's half-day turnover was 783 billion yuan, a decrease of 95.7 billion yuan from the previous day. More than 2,200 stocks fell in the market. In terms of sector themes, the CSSC, cross-border payment, diversified finance, real estate, electricity, and football sectors led the gains; CPO, diet pills, energy metals, and humanoid robot concept stocks led the declines. On the market, the power sector rose collectively, Huayin Power hit 4 boards in 5 days, and Shaoneng Shares and New China Port hit 2 consecutive boards. The real estate sector rose in the morning, and stocks such as Chongqing Development, Shahe Shares, and Nanshan Holdings hit the daily limit. Cross-border payment, diversified finance, and digital currency concept stocks fluctuated higher during the session, and many stocks of Xinyada, Beijing North, and Qingdao Kingwang hit the daily limit. Football concept stocks performed actively, and Gongchuang Lawn and Shuangxiang Shares both hit the daily limit. CPO concept stocks collectively adjusted, Zhongji Xuchuan, Tianfu Communication, and Dekeli fell more than 4%. Weight loss drug concept stocks rose and fell, Sinovac fell more than 8%, Yipinhong, Kailaiying, and Ganli Pharmaceuticals followed suit. 6G and communication sectors fluctuated downward, Yaguang Technology fell more than 9%, Longsheng Technology and Ruijie Networks fell the most.

2025.06.24

02:55

Amgen's stock price fell 7% after the results of the clinical trial of its experimental weight loss drug were released

Amgen was last down 7% after the company released clinical trial results for its experimental weight-loss drug.

Email Subscription

Newsletters and emails are now available! Delivered on time, every weekday, to keep you up to date with North American business news.

Weekly Highlights

                                    Novo Nordisk (NVO.N): The downward revision of its fiscal year sales forecast is related to declining sales of its weight loss drug Wegovy in the United States.
                            2025-07-29

                                    Toyota Motor Corp. is expected to decide as early as Wednesday evening whether to resume operations at its Japanese factories.
                            2025-07-30

                                    The world's first active safety AI battery cell goes into mass production
                            2025-07-27

                                    CATL's losses widened in the afternoon, with A shares falling more than 4% to below 280 yuan and H shares falling more than 7%.
                            2025-07-30

                                    BYD: Sales of new energy vehicles in July were 344,296 units. The cumulative sales of new energy vehicles from January to July were 2,490,250 units, a year-on-year increase of 27.35%.
                            2025-08-01